BCRX · BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals has entered a strategic licensing agreement with an Irish affiliate of Neopharmed Gentili S.p.A., granting exclusive rights to commercialize its investigational long-acting plasma kallikrein inhibitor, navenibart, for hereditary angioedema (HAE) in Europe. This deal provides BioCryst with $70 million in upfront cash, bolstering its balance sheet, alongside potential milestone payments totaling up to $275 million tied to regulatory approvals and sales performance, and tiered royalties of 18% to 30% on net sales. The transaction builds directly on a prior 2025 agreement where Neopharmed Gentili acquired BioCryst's European ORLADEYO business, leveraging the partner's established commercial infrastructure and HAE expertise in the region for execution continuity. Management highlights the rationale: it optimizes BioCryst's commercial focus by dedicating U.S. resources to ORLADEYO and navenibart domestically while enhancing launch readiness and patient access in Europe. CEO Charlie Gayer emphasized the partnership's role in delivering U.S. commercial excellence and financial strength, providing capital deployment optionality. Neopharmed Gentili's CEO Alessandro Del Bono noted it reinforces their rare disease leadership. With navenibart's Phase 3 program progressing toward a U.S. regulatory filing by end-2027, this non-dilutive financing retains significant upside for shareholders through milestones and royalties without ceding U.S. rights.